00:00
Growing Money
Growing Money
USD/RUB
EUR/RUB
Energy

U.S. Targets Madagascar in Bid to Break China’s Rare Earths Monopoly

Washington is expanding its reach into Africa’s critical minerals sector, committing $4.84 million to Harena Rare Earths’ Ampasindava project in Madagascar. This move aims to secure high-value magnet elements—including neodymium and dysprosium—as the U.S. intensifies its campaign to loosen Beijing’s grip on the global supply chain for advanced technology.

U.S. Targets Madagascar in Bid to Break China’s Rare Earths Monopoly

The U.S. International Development Finance Corporation funding targets pilot operations and environmental testing at the Ampasindava ionic clay deposit. While the initial investment is modest, successful milestones could unlock significant construction financing for the $150 million project. The site is projected to yield 4,000 metric tons of rare earth oxides annually, providing a strategic alternative to the Chinese processing infrastructure that currently dominates nearly 90% of the global market.

This initiative follows a pattern of U.S. intervention across the continent, mirroring a $1.87 million grant awarded earlier to Altona Rare Earths for the Monte Muambe project in Mozambique. By backing these ventures, the State Department seeks to counter what officials describe as predatory investment practices from adversaries. The strategy extends to domestic soil as well, where the Department of Defense has secured supply chain partnerships with MP Materials and USA Rare Earth to guarantee the production of permanent magnets essential for military systems and electric vehicles.

Beijing has responded to these efforts with retaliatory export controls and the blacklisting of major U.S. mining firms. As trade tensions escalate, the competition for non-Chinese mineral sources has become a central pillar of American industrial policy, shifting the focus toward African development corridors to insulate critical technology sectors from future export blockades.

Share

Comments (0)

Leave a comment

No comments yet. Be the first!